9 September 2024
CRISM Therapeutics
Corporation
("CRISM",
"CRISM Therapeutics" or the "Company")
Notice of Interim Results and
Presentation via Investor Meet Company
CRISM Therapeutics Corporation (AIM:
CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs,
will announce its Interim Results for the six months ended 30 June
2024 on Thursday, 19 September 2024.
Andrew Webb, CEO of CRISM
Therapeutics, will provide a live presentation via Investor Meet
Company on 19 September 2024 at 12.00pm BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via the Investor Meet Company dashboard up until 18
September 2024, 9.00am BST, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet CRISM Therapeutics
via:
https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor
Investors who already follow the
Company on the Investor Meet Company platform will automatically be
invited.
-Ends-
Enquiries:
|
Company
|
Nomad and
Broker
|
Financial
PR
|
|
CRISM Therapeutics
Corporation
|
S.P. Angel Corporate Finance
LLP
|
Burson
Buchanan
|
|
Andrew
Webb, CEO
Chris
McConville, CSO
|
Richard
Morrison
Adam
Cowl
|
Mark
Court / Jamie Hooper
CRISM@buchanancomms.co.uk
|
|
via
Burson Buchanan
|
+44 (0)
20 3470 0470
|
+44 (0)
20 7466 5000
|
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has
developed an innovative drug delivery technology to improve the
clinical performance of cancer treatments for solid tumours through
the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can
be implanted directly into the tumour or the resection margin
following the removal of a tumour. This directs that therapeutic
concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of
treating high-grade glioma, ChemoSeeds can be implanted during
surgery thereby bypassing the blood brain barrier, which prevents
other treatments from being able to reach the tumour and be
effective.
CRISM plans to submit a clinical
trial application in H2 2024 for ChemoSeed® in high-grade
glioma. Based on
preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory
Board has approved ChemoSeed in a phase II platform clinical trial
which is an efficient and cost-effective clinical development
opportunity.
For more information please
visit: https://www.crismtherapeutics.com/